Drug intelligence / Profile preview

AB-300

Development stage: Phase 1
Lead developer: Ariadne
Modality: Small Molecules
Administration: Oral

Overview

AB-300 (Ariadne Bio-300) is a first-in-class, non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist under development by Ariadne Bio, a company of Negev Labs. It is being developed to treat non-motor symptoms of Parkinson's disease (specifically apathy and motivational deficits) as well as late-life depression and neurodegeneration. In preclinical rodent studies, AB-300 reversed motivational deficits induced by the dopamine-depleting agent tetrabenazine, with effects comparable to the norepinephrine-dopamine reuptake inhibitor bupropion. A Phase 1b clinical trial is targeted to initiate in Q3 2026.

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on AB-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-300.